>
Former White House Advisor: "Trump to Release $150 Trillion Endowment"
The Mayo Clinic just tried to pull a fast one on the Trump administration...
'Cyborg 1.0': World's First Robocop Debuts With Facial Recognition And 360° Camera Visio
Dr. Aseem Malhotra Joins Alex Jones Live In-Studio! Top Medical Advisor To HHS Sec. RFK Jr. Gives...
'Cyborg 1.0': World's First Robocop Debuts With Facial Recognition And 360° Camera Visio
The Immense Complexity of a Brain is Mapped in 3D for the First Time:
SpaceX, Palantir and Anduril Partnership Competing for the US Golden Dome Missile Defense Contracts
US government announces it has achieved ability to 'manipulate space and time' with new tech
Scientists reach pivotal breakthrough in quest for limitless energy:
Kawasaki CORLEO Walks Like a Robot, Rides Like a Bike!
World's Smallest Pacemaker is Made for Newborns, Activated by Light, and Requires No Surgery
Barrel-rotor flying car prototype begins flight testing
Coin-sized nuclear 3V battery with 50-year lifespan enters mass production
BREAKTHROUGH Testing Soon for Starship's Point-to-Point Flights: The Future of Transportation
The ability to engineer particles that can enter a human body and transport a drug directly to a targeted cell is revolutionizing how medicine is delivered. A team of researchers from the University of Illinois has now created a new nanoparticle therapy that can target and destroy cancer stem cells to stop the disease returning.
The fear of relapse is one that constantly haunts cancer patients after any initial treatment has moved the disease into remission, but understanding how and why cancer returns eluded scientists for many years. In the mid-1990s, researcher John Dick first identified cancer stem cells, upending the field of cancer research and pointing to an entirely new area of study for scientists.
The discovery was that some cancers can be generated by these cancer stem cells (CSCs), and many existing treatments, while effective in destroying fast-growing cancer cells, completely miss these CSCs.